ASX:MVP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Medical Developments International

Executive Summary

Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment.


Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has Medical Developments International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MVP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.5%

MVP

-2.0%

AU Pharmaceuticals

4.0%

AU Market


1 Year Return

47.0%

MVP

-6.6%

AU Pharmaceuticals

-7.0%

AU Market

Return vs Industry: MVP exceeded the Australian Pharmaceuticals industry which returned -6.6% over the past year.

Return vs Market: MVP exceeded the Australian Market which returned -7% over the past year.


Shareholder returns

MVPIndustryMarket
7 Day-1.5%-2.0%4.0%
30 Day3.6%5.8%12.2%
90 Day-2.3%13.3%-2.5%
1 Year47.9%47.0%-6.4%-6.6%-3.1%-7.0%
3 Year47.0%43.7%-19.4%-20.2%19.0%3.3%
5 Year230.6%219.3%-24.5%-28.4%33.9%5.0%

Price Volatility Vs. Market

How volatile is Medical Developments International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medical Developments International undervalued compared to its fair value and its price relative to the market?

444.34x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: MVP (A$7.76) is trading above our estimate of fair value (A$0.46)

Significantly Below Fair Value: MVP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MVP is poor value based on its PE Ratio (444.3x) compared to the Pharmaceuticals industry average (18.7x).

PE vs Market: MVP is poor value based on its PE Ratio (444.3x) compared to the Australian market (16x).


Price to Earnings Growth Ratio

PEG Ratio: MVP is poor value based on its PEG Ratio (6.5x)


Price to Book Ratio

PB vs Industry: MVP is overvalued based on its PB Ratio (11.3x) compared to the AU Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

68.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MVP's forecast earnings growth (68.1% per year) is above the savings rate (2.3%).

Earnings vs Market: MVP's earnings (68.1% per year) are forecast to grow faster than the Australian market (15% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MVP's revenue (30.8% per year) is forecast to grow faster than the Australian market (4.2% per year).

High Growth Revenue: MVP's revenue (30.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (7.6%).


Next Steps

Past Performance

How has Medical Developments International performed over the past 5 years?

-12.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MVP has a high level of non-cash earnings.

Growing Profit Margin: MVP's current net profit margins (5.2%) are higher than last year (1.3%).


Past Earnings Growth Analysis

Earnings Trend: MVP's earnings have declined by -12.7% per year over the past 5 years.

Accelerating Growth: MVP's earnings growth over the past year (362.1%) exceeds its 5-year average (-12.7% per year).

Earnings vs Industry: MVP earnings growth over the past year (362.1%) exceeded the Pharmaceuticals industry 28.6%.


Return on Equity

High ROE: MVP's Return on Equity (2.6%) is considered low.


Next Steps

Financial Health

How is Medical Developments International's financial position?


Financial Position Analysis

Short Term Liabilities: MVP's short term assets (A$32.3M) exceed its short term liabilities (A$8.6M).

Long Term Liabilities: MVP's short term assets (A$32.3M) do not cover its long term liabilities (A$34.0M).


Debt to Equity History and Analysis

Debt Level: MVP's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: MVP's debt to equity ratio has reduced from 9.5% to 0.4% over the past 5 years.

Debt Coverage: MVP's debt is well covered by operating cash flow (681.3%).

Interest Coverage: MVP earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Medical Developments International's current dividend yield, its reliability and sustainability?

0.52%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: MVP's dividend (0.52%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.47%).

High Dividend: MVP's dividend (0.52%) is low compared to the top 25% of dividend payers in the Australian market (6.45%).


Stability and Growth of Payments

Stable Dividend: MVP is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: MVP is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: MVP is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

John Sharman (53yo)

10.17yrs

Tenure

AU$643,987

Compensation

Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, serves as Chief Executive Officer at Universal Biosensors, Inc. since 2020. He serves as Investment Director of CVC Venture Managers Pty Limited. Mr. Sharman  ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD449.90K) is below average for companies of similar size in the Australian market ($USD764.04K).

Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Sharman
Chief Executive Officer10.17yrsAU$643.99k0.0079% A$40.2k
Mark Edwards
CFO & Company Secretary2.67yrsAU$249.38kno data
Wayne Pearce
Head of Operations0.92yrno datano data
Thomas Materia
Head of Sales & Marketing0.92yrno datano data
Tara Collier
Head of Human Resources0.92yrno datano data
Scott Courtney
Chief Scientific Officer0.92yrno datano data
Michelle Bradney
Head of Medical Affairs1.83yrsno datano data
Wai Chi
Head of Regulatory Affairs1.58yrsno datano data
Neil Issa
Head of Quality1.42yrsno datano data
Matthew Cramer
Head of Project Management Office0.92yrno datano data

1.2yrs

Average Tenure

Experienced Management: MVP's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Philip Powell
Non-Executive Director5.5yrsAU$51.25k0.40% A$2.1m
David Williams
Non Executive Chairman16.75yrsAU$83.33k13.13% A$66.9m
R. Johnston
Non-Executive Director7.58yrsAU$51.25k0.061% A$309.4k
Leon Hoare
Non-Executive Director6.75yrsAU$51.25k0.022% A$109.6k
Christine Emmanuel
Non-Executive Director0.083yrno datano data

6.8yrs

Average Tenure

Experienced Board: MVP's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medical Developments International Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medical Developments International Limited
  • Ticker: MVP
  • Exchange: ASX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$509.238m
  • Shares outstanding: 65.62m
  • Website: https://www.medicaldev.com

Number of Employees


Location

  • Medical Developments International Limited
  • 4 Caribbean Drive
  • Scoresby
  • Victoria
  • 3179
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MVPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2003
MDDV.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2003
MVPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2003

Biography

Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment. The company operates in three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in homes, pharmacies, hospitals, medical practices, and aged care facilities; Penthrox, a prescription only medicine for pain relief; medical devices; and various veterinary anesthetic machines to veterinarians. The company operates in Australia, New Zealand, Italy, rest of Europe, the United Kingdom, Canada, the Middle East, South Africa, North America, Rest of Asia, and internationally. Medical Developments International Limited is headquartered in Scoresby, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 10:36
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.